Nivolumab in Previously Untreated Melanoma without BRAF Mutation C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ... New England journal of medicine 372 (4), 320-330, 2015 | 6024 | 2015 |
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 2868 | 2019 |
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2486 | 2017 |
Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial PA Ascierto, GV Long, C Robert, B Brady, C Dutriaux, AM Di Giacomo, ... JAMA oncology 5 (2), 187-194, 2019 | 346 | 2019 |
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis R Duchnowska, R Pęksa, B Radecka, T Mandat, T Trojanowski, B Jarosz, ... Breast Cancer Research 18, 1-11, 2016 | 113 | 2016 |
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations P Krawczyk, DM Kowalski, R Ramlau, E Kalinka‑Warzocha, K Winiarczyk, ... Oncology letters 13 (6), 4433-4444, 2017 | 72 | 2017 |
MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or … E Van Cutsem, HJ Lenz, J Furuse, J Tabernero, V Heinemann, T Ioka, ... Journal of Clinical Oncology 34 (15_suppl), 4007-4007, 2016 | 69 | 2016 |
Guidelines for the diagnosis and management of osteoporosis in Poland: Update 2017 R Lorenc, P Głuszko, E Franek, M Jabłoński, M Jaworski, ... Endokrynologia Polska 68 (5), 604-609, 2017 | 48 | 2017 |
The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study P Krawczyk, R Ramlau, J Chorostowska-Wynimko, T Powrózek, ... Journal of cancer research and clinical oncology 141, 61-68, 2015 | 47 | 2015 |
Czerniaki skóry—zasady postępowania diagnostyczno-terapeutycznego w 2016 roku P Rutkowski, PJ Wysocki, A Nasierowska-Guttmejer, J Fijuth, ... Onkologia w Praktyce Klinicznej-Edukacja 1 (1), 37-53, 2015 | 46 | 2015 |
Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma P Centkowski, L Brydak, M MachaŁa, E Kalinka-Warzocha, ... Journal of Clinical Immunology 27, 339-346, 2007 | 45 | 2007 |
Cutaneous melanoma P Rutkowski, PJ Wysocki, A Nasierowska-Guttmejer, A Jeziorski, ... Oncology in clinical practice 16 (4), 163-182, 2020 | 42 | 2020 |
Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum-and gemcitabine-based chemotherapy in non-small cell lung cancer patients R Mlak, P Krawczyk, R Ramlau, E Kalinka-Warzocha, ... Oncology reports 30 (5), 2385-2398, 2013 | 39 | 2013 |
Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma … E Van Cutsem, HJ Lenz, J Furuse, J Tabernero, V Heinemann, T Ioka, ... Journal of Clinical Oncology 34 (4_suppl), 193-193, 2016 | 38 | 2016 |
Zalecenia postępowania diagnostycznego i leczniczego w osteoporozie w Polsce. Aktualizacja 2017 R Lorenc, P Głuszko, E Franek, M Jabłoński, M Jaworski, ... Endokrynologia Polska 68 (A), 1-18, 2017 | 35 | 2017 |
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases R Duchnowska, J Sperinde, A Chenna, W Huang, JM Weidler, J Winslow, ... Neuro-oncology 17 (9), 1241-1249, 2015 | 34 | 2015 |
Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients P Krawczyk, T Kucharczyk, DM Kowalski, T Powrózek, R Ramlau, ... Journal of cancer research and clinical oncology 140, 2047-2057, 2014 | 34 | 2014 |
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low‐grade B‐cell non … E Kalinka‐Warzocha, J Wajs, E Lech‐Maranda, B Ceglarek, J Holowiecki, ... Cancer 113 (2), 367-375, 2008 | 30 | 2008 |
Cutaneous melanomas P Rutkowski, PJ Wysocki Forum Dermatologicum 4 (1), 17-35, 2018 | 28 | 2018 |
Two-year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066 V Atkinson, PA Ascierto, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, ... Journal of Translational Medicine 14, 2016 | 28 | 2016 |